Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407188 | 0.83 | NNMT (0.56) | NNMTSMN1; SMN2L3MBTL1KDM4EF7 | |
| SCHEMBL3141529 | 0.79 | NNMT (0.58) | NNMTSMN1; SMN2L3MBTL1KDM4EF7 | |
| SCHEMBL669121 | 0.79 | NNMT (0.52) | NNMTSMN1; SMN2L3MBTL1KDM4EF7 | |
| SCHEMBL1968189 | 0.77 | NNMT (0.50) | NNMTSMN1; SMN2L3MBTL1KDM4EF7 | |
| SCHEMBL23193160 | 0.77 | NNMT (0.50) | NNMTSMN1; SMN2L3MBTL1KDM4EF7 | |
| SCHEMBL5790116 | 0.77 | NNMT (0.45) | NNMTSMN1; SMN2L3MBTL1KDM4EF7 | |
| SCHEMBL185448 | 0.76 | ALDH1A1 (0.54) | SMN1; SMN2KDM4ETSHRPOLBMAPT | |
| SCHEMBL3407187 | 0.75 | NNMT (0.48) | NNMTSMN1; SMN2L3MBTL1KDM4EF7 | |
| SCHEMBL13160131 | 0.74 | CA5A (0.44) | SMN1; SMN2L3MBTL1KDM4EMAPTHSD17B10 | |
| SCHEMBL447959 | 0.73 | NNMT (0.63) | NNMTSMN1; SMN2L3MBTL1KDM4EF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153636-A | Cyclopropyl-amide compound as dual LSD1/HDAC inhibitor | 朱比连特比利斯有限公司 | 2019-01-04 | — | — | CN | claimed |
| WO-2012117421-A1 | HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD (IN) | 2012-09-07 | — | — | WO | claimed |
| WO-2011083495-A2 | PROCESS FOR THE PREPARATION OF DIHYDROXY PROTECTED DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | MSN LABORATORIES LIMITED (IN) | 2011-07-14 | — | — | WO | claimed |
| CN-108997224-B | Preparation method of 2-chloro-5-cyano nitrogen-containing six-membered heterocyclic compound | 韶远科技（上海)有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| WO-2021066136-A1 | THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY | 国立大学法人東京大学 | 2021-04-08 | — | — | WO | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| CN-109942564-A | A kind of histon deacetylase (HDAC) inhibitor and its preparation method and application | 四川大学华西医院 | 2019-06-28 | — | — | CN | disclosed |
| CN-109923117-A | Use the combination therapy of the phosphoinositide 3-kinase inhibitor with zinc bound fraction | 柯瑞斯公司 | 2019-06-21 | — | — | CN | disclosed |
| CN-109715173-A | HDAC inhibitors for use in NK cell based therapies | 维拉克塔治疗公司 | 2019-05-03 | — | — | CN | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| CN-102970868-A | Treatment of cancers having K-RAS mutations | CURIS INC | 2013-03-13 | — | — | CN | disclosed |
| EP-2557923-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | Curis, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2385832-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | Curis, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-8040979-B2 | Generating a phase value for a complex signal | INFINEON TECHNOLOGIES AG (DE) | 2011-10-18 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| WO-2011083495-A2 | PROCESS FOR THE PREPARATION OF DIHYDROXY PROTECTED DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | MSN LABORATORIES LIMITED (IN) | 2011-07-14 | — | — | WO | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | NNMT 238/4885SMN1; SMN2 4142/4885L3MBTL1 257/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | NNMT 2084/4885SMN1; SMN2 249/4885L3MBTL1 659/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | NNMT 1824/4885SMN1; SMN2 191/4885L3MBTL1 443/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | NNMT 2154/4885SMN1; SMN2 263/4885L3MBTL1 656/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | NNMT 238/4885SMN1; SMN2 4142/4885L3MBTL1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.